Study of rhASB in Patients With Mucopolysaccharidosis VI

Completed · Phase 3 · Has a placebo group

Conditions studied: Mucopolysaccharidosis VI

In brief

The purpose of this study is to evaluate the long-term efficacy and safety of rhASB treatment in patients with Mucopolysaccharidosis VI.

Key facts

Study ID

NCT00104234

Run by

BioMarin Pharmaceutical

People needed

39

Starts

2004-02-01

Expected to finish

2006-10-01

Last updated by the study team

2010-02-02

Who can join

Age: 7 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patient consent
• Patient must have successfully completed study ASB-03-05, including having received at least 20 of 24 scheduled weekly infusions and having missed no more then two consecutive infusions
• If female of childbearing potential, patient must have a negative pregnancy test

You may not qualify if…

• Pregnant or lactating patient
• Patient has received an investigational drug within 30 days prior to study enrollment
• Patient is unwilling or unable to travel to the primary site for periodic assessments

Where it is running

• BioMarin Pharmaceutical Inc. — Novato, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.